Analysts Set Encompass Health Corporation (NYSE:EHC) Price Target at $139.86

Shares of Encompass Health Corporation (NYSE:EHC) have earned a consensus rating of “Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $139.8571.

EHC has been the subject of a number of research analyst reports. UBS Group upped their price target on Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, October 2nd. Zacks Research raised Encompass Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 21st. Truist Financial increased their price objective on Encompass Health from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Bank of America increased their price objective on Encompass Health from $145.00 to $160.00 and gave the company a “buy” rating in a report on Wednesday, September 10th. Finally, KeyCorp increased their price objective on Encompass Health from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th.

Insider Activity at Encompass Health

In other news, EVP Patrick William Tuer sold 1,020 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the sale, the executive vice president owned 18,846 shares in the company, valued at $2,329,177.14. This represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its position in shares of Encompass Health by 21.5% in the first quarter. GAMMA Investing LLC now owns 2,366 shares of the company’s stock valued at $240,000 after buying an additional 419 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of Encompass Health by 30.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 9,597 shares of the company’s stock valued at $972,000 after buying an additional 2,218 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Encompass Health by 6.7% in the first quarter. Sequoia Financial Advisors LLC now owns 2,727 shares of the company’s stock valued at $276,000 after buying an additional 172 shares in the last quarter. Highland Capital Management LLC purchased a new position in shares of Encompass Health in the first quarter valued at $206,000. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Encompass Health by 51.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 69,231 shares of the company’s stock valued at $7,012,000 after buying an additional 23,518 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Down 0.5%

Shares of NYSE:EHC opened at $125.65 on Monday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market capitalization of $12.65 billion, a PE ratio of 24.59, a price-to-earnings-growth ratio of 2.21 and a beta of 0.93. The firm’s 50-day moving average is $124.50 and its two-hundred day moving average is $118.81. Encompass Health has a 1 year low of $87.85 and a 1 year high of $127.99.

Encompass Health (NYSE:EHC) last released its earnings results on Wednesday, March 16th. The company reported $0.93 earnings per share for the quarter. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The firm had revenue of $136.30 million for the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. Analysts predict that Encompass Health will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Friday, January 2nd will be paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, January 2nd. Encompass Health’s dividend payout ratio is 14.87%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.